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Abstract

NIH-PA Author Manuscript

Uch37 is a de-ubiquitylating enzyme that is functionally linked with the 26S proteasome via
Rpn13, and is essential for metazoan development. Here, we report the X-ray crystal structure of
full-length human Uch37 at 2.95 Å resolution. Uch37's catalytic domain is similar to those of all
UCH enzymes characterized to date. The C-terminal extension is elongated, predominantly helical
and contains coiled coil interactions. Additionally, we provide an initial characterization of
Uch37's oligomeric state and identify a systematic error in previous analyses of Uch37 activity.
Taken together, these data provide a strong foundation for further analysis of Uch37's several
functions.
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Introduction
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Uch37 is a de-ubiquitylating enzyme (DUB) that is functionally linked with multiple protein
complexes and signal transduction pathways. Uch37 associates with the 26S proteasome1
through Rpn132 where it serves to remove distal ubiquitin moieties from polyubiquitylated
proteins.1 Uch37's proteasome associated activity was shown to liberate proteins from
destruction.1 However, Uch37 may also specifically facilitate the destruction of inducible
nitric oxide synthase and IκB-α at the proteasome.3 Wicks et al.4 established Uch37's
potential to modulate the transforming growth factor-β(TGF-β) signaling cascade, through
its interaction with SMAD7. Yao et al.5 demonstrated that Uch37 also associates with the
Ino80 chromatin-remodeling complex (Ino80 complex), which is involved in DNA repair
and transcriptional regulation. Uch37's importance in metazoan development was
underscored recently as Uch37 knockouts in mice result in prenatal lethality, where mutant
embryos had severe defects in brain development.6
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Protein ubiquitylation is an ATP-dependent post-translational modification that serves to
signal a wide variety of cellular processes in eukaryotes.7,8 A protein cascade, generally
comprising three enzymes, functions to activate, transport and specifically transfer ubiquitin
to the targeted protein, culminating in an isopeptide linkage between the ε-amino group of a
target protein's lysyl residue and the ubiquitin's terminal carboxylate.9 Monoubiquitylation
plays an important role in histone regulation, endocytosis and viral budding.10 Further
processing of the target protein may be accomplished by ubiquitylation of the protein on a
different lysine, or through the formation of polyubiquitin chains,10 where the bestcharacterized outcome is destruction of the polyubiquitin-labeled protein in the proteasome.9
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DUBs catalyze the removal of ubiquitin from proteins. This activity serves to reverse the
effects of ubiquitination, permit ubiquitin recycling, or liberate free ubiquitin after
translation.11 Uch37, is a cysteine protease from the ubiquitin C-terminal hydrolase (UCH)
family.7 The catalytic domain of UCH enzymes has a central, six-stranded, antiparallel βsheet that is flanked on each side by α-helices.12 Like picornain 3C, UCH family proteins
contain a catalytic triad comprising the side chains of cysteine, histidine, and aspartate. In
picornain 3C, the aspartate's carboxylate side chain acts to position histidine's imidazole
group for general base catalysis, which activates cysteine for nucleophilic attack.13 UCH
enzymes also contain a glutamine, which may serve to stabilize the tetrahedral transition
state.11 The UCH family can be divided into two distinct groups, i.e., enzymes solely
composed of the globular UCH fold, or enzymes comprising the UCH domain and a Cterminal extension. The latter group can be subdivided based on the composition of the Cterminal extension.14 Uch37 carries a C-terminal extension. Until now the structure of a fulllength UCH from this structural class has not been reported.
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In this article we report the X-ray crystal structure of full-length human Uch37 at 2.95 Å
resolution. This model provides a structural rationale for the accessibility of Uch37's Cterminus for Rpn13 binding. The globular catalytic domain of full-length Uch37 is similar to
those of all UCHs characterized to date.12,15-17 The C-terminal extension is elongated,
predominantly helical and as predicted contains coiled coils.11 Chromatographic analysis of
Uch37 demonstrated that Uch37's oligomeric state varies as a function of concentration.
Uch37's specific activity is sensitive to Uch37 concentration in the absence of a non-specific
binding agent, but nearly constant and an order of magnitude higher in the presence of BSA.
These data show that activity assays of isolated Uch37 at low protein concentration suffers
from a serious systematic error and suggests that the effects of Uch37 binding proteins on
Uch37's activity from previous reports may be misleading. After our Uch37 coordinates
were released by the PDB18, Nishio et al.17 reported the structure of the UCH domain of
Uch37. The work presented here both verifies and expands upon their findings.

Materials and Methods
Expression and purification of Uch37
The Center for Eukaryotic Structural Genomics platform for cloning,19 protein expression,20
protein purification,21 and bioinformatics management22 was utilized to produce
selenomethione labeled Uch37 (isoform 3). Uch37 cDNA was cloned into a pDONR221
plasmid (Invitrogen, Carlsbad, CA), and transferred into the pVP16 expression plasmid
Proteins. Author manuscript; available in PMC 2013 February 02.
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(derived from pQE80, Qiagen, Valencia, CA). Uch37 was expressed in Escherichia coli
B834 p(RARE2) cells in 2 L of self-inducing media. Cell pastes were sonicated and
centrifuged. Uch37 was purified from the supernatant by nickel affinity chromatography.
TEV protease was used to cleave the His-maltose-binding protein tag,23 and Uch37 was
purified from the tag and TEV protease by nickel affinity chromatography. Uch37 was
exchanged into its final buffer via gel filtration chromatography (0.3 mM tris(2carboxyethyl)phosphine and 5 mM BisTris, pH 7.0). Uch37 was concentrated to 10
mg*mL-1, flash frozen in liquid nitrogen and stored at 193 K. These processes yielded 12.0
mg of selenomethionine-labeled Uch37.
Uch37 Crystallization and structure solution
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Crystal growth conditions were identified using the 192-condition UW192 screen (CESG,
Madison, Wisconsin), and Salt Rx HT and Index HT screens (Hampton Research, Aliso
Viejo, California). Sitting drop vapor diffusion screens were assembled with a Mosquito
crystallization robot (TTP Labtech, Ltd., Royston, UK). Crystals were grown and monitored
in Crystal Farms (Bruker AXS, Inc., Madison, Wisconsin) at 4°C and 20°C. Solutions for
crystal optimization were assembled with a Genesis RSP 150 robot (Tecan Group, Ltd.,
Männedorf, Switzerland) with work lists generated by the Sesame laboratory information
management system (University of Wisconsin-Madison). Diffraction quality crystals were
grown in hanging drop batch experiments at 4°C. Samples were assembled on siliconized
cover slips by mixing 2 μl of Uch37 stock solution with 2 μl of precipitant solution (2.6 M
sodium formate and 200 mM Tris, pH 8.5), seeded with crushed Uch37 crystals, and
incubated in sealed acrylic batch trays. Crystals grew to dimensions of 200 μm × 200 μm ×
200 μm after two weeks. Crystals were transferred to artificial mother liquor (1.3 M sodium
formate and 100 mM Tris, pH 8.5), and then to a cryoprotectant solution (1.5 M sodium
formate, 100 mM Tris, pH 8.5 and 20% ethylene glycol) through three intermediate
solutions. The crystals were flash frozen in a 100 K nitrogen stream.
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X-ray diffraction data were collected at the General Medicine and Cancer Institute
Collaborative Access Team 23-ID-D Beamline at the Argonne National Laboratory's
Advanced Photon Source (Argonne, Illinois). Datasets were collected at the selenium peak
and edge wavelengths from a single crystal. The datasets were indexed, integrated and
scaled using HKL2000.24 The selenium substructure was characterized using Phenix.hyss25
and ShelXD.26,27 Refinement of the selenium positions with automated density modification
was conducted with AutoSharp.28 A workable preliminary model was produced using the
ACMI software package (Version 1.3).29,30 Manual model building with the program
COOT31 and refinement with Phenix32 using seven TLS groups were conducted en route to
generating the final model. Initial TLS groups were determined using TLSMD.33,34 Model
validation was conducted using Molprobity35 and Procheck.36 Superposition analyses of
Uch37 with homologous proteins were conducted using LSQKAB.37
Analysis of Uch37's oligomeric state
Analytical size exclusion gel chromatography was conducted using a 24 ml Superdex 200
GL column (GE Healthcare, Piscataway, New Jersey) with an Äkta FPLC chromatographic
system (GE Healthcare) at 4°C. 25 μl of sample were loaded per run. Protein elution was
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monitored by UV-spectroscopy at 280 nm. The elution buffer comprised 200 mM NaCl, 1
mM tris(2-carboxyethyl)phosphine, and 50 mM HEPES, pH 7.5 at 4°C. The column was
calibrated with blue dextran, bovine γ-globulin, bovine serum albumin, chicken ovalbumin
and equine myoglobin. Buried surface area was calculated using PISA.38
Uch37 reaction kinetics
All kinetic assays were conducted at 25°C, in 200 mM NaCl, 1 mM dithiothreitol, 4%
dimethylsulfoxide, 10 μM ubiquitin-AMC (Boston Biochem) and 100 mM HEPES, pH 7.5
at 25°C. When included in solution, BSA was added to 2 mg*ml-1. Uch37 was included to
0.25, 1 or 4 nM. Reactions were initiated by the addition of ubiquitin-AMC, and samples
were manually mixed. Reaction progress was monitored using a QuantaMaster Model
C-60/2000 Spectrofluorimeter (Photon Technologies International, Birmingham, New
Jersey) using an excitation wavelength of 380 nM and an emission wavelength of 460 nM.

Results and Discussion
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The structure of Uch37 was solved to a resolution of 2.95 Å. Selenomethionine-labeled
Uch37 crystallized in the I222 space group with one polypeptide chain per asymmetric unit.
Initial phases were calculated by multiple-wavelength anomalous dispersion (MAD).
ACMI29,30 provided an initial model of Uch37's catalytic domain, and traced the Uch37 Cterminal extension to facilitate model building. Data collection and refinement statistics are
listed in Table I.
Uch37 comprises an N-terminal catalytic domain characteristic of the UCH family, and an
extended C-terminal extension (Figure 1A). Residues 1-6 and 145-161 of the catalytic
domain, and 249-254 and 312-328 of the C-terminal domain were not modeled for lack of
interpretable electron density. The presence of the C-terminal extension does not
significantly alter the overall fold of the isolated catalytic domain as solved by Nishio et
al.17 Superposition of Uch37 with the ubiquitin-bound form of UCH-L316 reveals that the
contacts observed between UCH-L3 and ubiquitin can be translated into plausible Uch37ubiquitin contacts (Figure 1B), and that the crystallographic orientation of the C-terminal
domain would not hinder ubiquitin binding.
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The C-terminal domain comprises α-helices 8-10, and a helical segment comprising residues
306-311. The absence of electron density for residues 312 through 328 suggests that this
segment, which is essential for Rpn13 binding,39 may be freely accessible. Helix 8
comprises residues 227 through 245. In a truncation mutant containing the N-terminal 240
amino acids, Helix 8 appears to form spontaneously (Prof. Chittaranjan Das, personal
communication). Helix 8 forms a coiled-coil with residues 255 through Glu273 of Helix 9.
The coiled coil was predicted previously,11 and receives its integrity from several
hydrophobic interactions throughout its length. Interestingly, within the crystal this coiled
coil places Helix 9 in position to interact with bound ubiquitin near ubiquitin's Lys48 (Fig
1C), and could potentially serve to enforce Uch37's selectivity for the distal ubiquitin of
polyubiquitin chains.
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Uch37 forms a homotetramer with D2 symmetry within the crystal (Figure 1D). The
tetramer assembles as a dimer of dimers. Dimers are formed as Helix 9 from the C-terminal
domain of one subunit interacts with the ubiquitin binding face of the catalytic domain from
a second subunit, and the C-terminal extensions of the two subunits cross between Helices 9
and 10 for a total buried surface area of 1861 Å2 per subunit. The dimers unite to form a
tetramer, primarily through coiled-coil interactions mediated by Helix 10 from each subunit.
Each set of contacts at the inter-dimer interface is related by D2 symmetry to three identical
interactions, and have a total buried surface area of 735 Å2 per subunit.
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Uch37's weight average molecular weight increases as a function of its concentration. By
size-exclusion chromatography, the apparent molecular weight of Uch37 was 51, 56, 70 and
109 kDa at 0.15, 0.69, 2.4 and 9.5 mg*ml-1, respectively. Given Uch37's monomeric
molecular weight of 37 kDa and its apparent elongated shape, it's tendency toward an
apparent molecular weight between 40 and 50 kDa at decreasing concentrations is
appropriate for Uch37 monomers. At the highest concentration the molecular weight was
increasing sharply as a function of concentration. Thus, the upper limit of Uch37's molecular
weight could not be estimated. Uch37 is clearly a self-associating molecule, but under the
conditions tested, oligomerization occurs at concentrations that may not be attainable within
the cell. However, the crystallographic tetramer is intriguing as it predicts Uch37 autoinhibition, as Helix 9 would occlude the ubiquitin binding-site. This affords the possibility
that under cellular conditions, e.g., through molecular crowding, small molecule association,
etc., free Uch37 could reside in an inert form until acted upon by the proteasome, Ino80
complex or other activity modulator.
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In vitro binding of Uch37 with Rpn13 was shown to promote the hydrolysis of ubiquitin-7amido-4-methylcoumarin (Ub-AMC) and Uch37's reactivity with suicide inhibitors such as
ubiquitin vinylsulfone (UbVS) and ubiquitin aldehyde (Ubal).2 Activation appeared to be
regulated in part by the C-terminal domain of Uch37,2 as removal of the residues 238-329
provided enhanced hydrolase activity. However, this modification did not restore the same
degree of activity that was achieved by the Rpn13-Uch37 complex.2 An alternative
explanation for these phenomena is the differential solubility of Uch37 at low
concentrations. To test this possibility we conducted assays of Uch37 to approximate
concentrations and conditions previously assayed2,5 with or without bovine serum albumin
(BSA) as a non-specific binding agent (Figure 1E). In the absence of BSA, Uch37 specific
activity was relatively low, and was highly dependent upon the Uch37 concentration. At
increasing Uch37 concentrations Uch37 specific activity increased dramatically. Two
processes could explain this, oligomerization of Uch37 yielding a more active form, or a
disproportionate loss of functional Uch37 through nonspecific binding. However, in the
presence of BSA, Uch37 specific activity was one to two orders of magnitude higher than it
was in the absence of BSA and constant as a function of concentration, suggesting the latter
mechanism. Thus, additives that could stabilize Uch37 solubility through a direct binding
event, e.g., Rpn13, or chemical modifications of Uch37 that may yield a more soluble form,
e.g., removal of the C-terminal tail could enhance Uch37's activity. These observations do
not preclude the possibility that Rpn13 enhances Uch37 activity. However, they do show the
presence of a serious systematic error in prior investigations that could lead to incorrect
assumptions of Uch37's activity.
Proteins. Author manuscript; available in PMC 2013 February 02.
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In conclusion, Uch37 consists of two domains, a globular UCH-domain and a fibrous Cterminal tail. The C-terminal residues of Uch37 implicated in Rpn13 binding appear to be
unstructured and solvent exposed. Uch37 undergoes a dynamic equilibrium between
monomers and higher order oligomers. Within the crystal, Uch37 is tetrameric with subunit
contacts that would preclude ubiquitin binding. However, the concentrations required for
oligomerization are high and would be unlikely to provide significant inhibition against
Uch37's activity unless cellular conditions promoted self-assembly. The rates of ubiquitinAMC hydrolysis by Uch37 are much higher in the presence of the non-specific binding
agent, BSA, than in its absence. This result reveals a systematic error in similar assays that
have been used to characterize the effects of mutations and Uch37 binding proteins on
Uch37 activity and function. Finally, our Uch37 structure provides a suitable molecular
model for probing the interactions of Uch37 with its various partner molecules.
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Figure 1. Uch37 structure and activity

(A) Uch37 is rendered as a cartoon stereodiagram. α-helices are labeled H1-H10, and βstrands are labeled S1-S6. Catalytic triad residues (Cys88, His 164 and Asp179) are
rendered as sticks and highlighted with yellow, and Gln82, which is putatively involved in
transition state stabilization is highlighted in blue. (B) The superposition of Uch37 (green)
with ubiquitin-bound UCH-L316 (blue) is illustrated as a stereodiagram. Ubiquitin is
displayed as a surface where carbon, oxygen and nitrogen atoms are colored white, red and
blue, respectively. Positions of ubiquitin residues are labeled for convenience. The Uch37
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catalytic cysteine is highlighted in yellow. (C) The relative position of Uch37's (green)
Helix 9 and the superposed ubiquitin (white) from the UCH-L3-ubiquitin complex is
displayed as a stereodiagram. (D) The crystallographic Uch37 tetramer is shown as a ribbon
diagram. Subunits are distinguished by color. (E) The relative specific activity of Uch37 in
the presence (□) or absence (○) of BSA are plotted as a function of Uch37 concentration.
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Crystal Parameters, Xray Data Collection, and Refinement Statistics
Peak

Inflection

I222

I222

90.0 × 98.7 × 154.0

90.1 × 98.7 × 154.0

Crystal parameters
Space group
Unit-cell parameters (Å)

a
Data collection statistics
Wavelength (Å)

0.97949

0.97973

50-2.95(3.10-2.95)

50-2.95(3.10-2.95)

No. of reflections

13687(1252)

13648(1243)

Completeness (%)

93.3(69.1)

92.8(68.3)

0.074(0.278)

0.057(0.292)

Redundancy

11.7(10.3)

11.7(10.0)

<I>/σ(I)

36.4(7.0)

36.9(6.1)

Resolution range (Å)

Rmerge

b

a

Refinement and model statistics

NIH-PA Author Manuscript

Resolution range (Å)

45.6-2.95(3.18-2.95)

No. of reflections (work/test)
Completeness (%)

13114/682
92.9(71)

c

0.201(0.248)

d

0.242(0.278)

RMSD bonds (Å)

0.007

RMSD angles (°)

1.09

Rcryst
Rfree

B factor- overall/protein/waters (Å)

107.2/107.1/70.0

e
No. of protein molecules/all atoms

1/2290

Ramachandran plot by MOLPROBITY (%)
Favored region

92.4

Additionally allowed region

7.6

Outliers
PDB code

0
3IHR

NIH-PA Author Manuscript

a

Values in parentheses are for the highest resolution shell.

b

Rmerge = ΣhΣi|Ii(h)-<I(h)>|/ΣhΣiIi(h), where Ii(h) is the intensity of an individual measurement of the reflection and <I(h)> is the mean intensity

of the the reflection.

c

Rcryst = Σh||Fobs|-|Fcalc||/Σh|Fobs|, where Fobs and Fcalc are the observed and calculated structure-factor amplitudes, respectively.

d

Rfree was calculated as Rcryst using the randomly selected unique reflections (~5%) that were omitted from structural refinement.

e
These include atoms from 10 water molecules, 2 formate ions, and one sodium ion.
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